Literature DB >> 11991532

Determination of MDMA and its metabolites in blood and urine by gas chromatography-mass spectrometry and analysis of enantiomers by capillary electrophoresis.

Nieves Pizarro1, Jordi Ortuño, Magí Farré, Cándido Hernández-López, Mitona Pujadas, Amadeu Llebaria, Jesús Joglar, Pere N Roset, Marta Mas, Jordi Segura, Jordi Camí, Rafael de la Torre.   

Abstract

A gas chromatography-mass spectrometry (GC-MS) method was used for the simultaneous quantitation of 3,4-methylenedioxymethamphetamine (MDMA) and the 3,4-methylenedioxyamphetamine (MDA), 4-hydroxy-3-methoxymethamphetamine (HMMA), and 4-hydroxy-3-methoxyamphetamine (HMA) metabolites in plasma and urine samples after the administration of 100 mg MDMA to healthy volunteers. Samples were hydrolyzed prior to a solid-phase extraction with Bond Elut Certify columns. Analytes were eluted with ethyl acetate (2% ammonium hydroxide) and analyzed as their trifluoroacyl derivatives. Linear calibration curves were obtained at plasma and urine concentration ranges of 25-400 ng/mL and 250-2000 ng/mL for MDMA and HMMA, and of 2.5-40 ng/mL and 100-1000 ng/mL for MDA and HMA. Following the same urine preparation procedure but without the derivatization step, a capillary electrophoresis (CE) method for enantiomerical resolution of compounds was developed using (2-hydroxy)propyl-beta-cyclodextrin at two different concentrations (10 and 50mM in 50mM H3PO4, pH 2.5) as chiral selector. Calibration curves for the CE method were prepared with the corresponding racemic mixture and were linear between 125 and 2000 ng/mL, 50 and 1000 ng/mL, and 125 and 1500 ng/mL for each enantiomer of MDMA, MDA, and HMMA, respectively. Stereoselective disposition of MDMA and MDA was confirmed. HMMA disposition seems to be in apparent contradiction with MDMA findings as the enantiomer ratio is close to 1 and constant over the time.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11991532     DOI: 10.1093/jat/26.3.157

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  27 in total

1.  MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers.

Authors:  Rafael de la Torre; Magí Farré; Brian O Mathúna; Pere N Roset; Neus Pizarro; Mireia Segura; Marta Torrens; Jordi Ortuño; Mitona Pujadas; Jordi Camí
Journal:  Eur J Clin Pharmacol       Date:  2005-07-23       Impact factor: 2.953

Review 2.  Modern instrumental methods in forensic toxicology.

Authors:  Michael L Smith; Shawn P Vorce; Justin M Holler; Eric Shimomura; Joe Magluilo; Aaron J Jacobs; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2007-06       Impact factor: 3.367

3.  Effects of repeated 3,4-methylenedioxymethamphetamine administration on neurotransmitter efflux and sensory-evoked discharge in the ventral posterior medial thalamus.

Authors:  M A Starr; M E Page; B D Waterhouse
Journal:  J Pharmacol Exp Ther       Date:  2011-10-07       Impact factor: 4.030

4.  Urinary excretion kinetics of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its phase I and phase II metabolites in humans following controlled MDMA administration.

Authors:  Andrea E Schwaninger; Markus R Meyer; Allan J Barnes; Erin A Kolbrich-Spargo; David A Gorelick; Robert S Goodwin; Marilyn A Huestis; Hans H Maurer
Journal:  Clin Chem       Date:  2011-10-06       Impact factor: 8.327

5.  Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2 h apart.

Authors:  A M Peiró; M Farré; P N Roset; M Carbó; M Pujadas; M Torrens; J Camí; R de la Torre
Journal:  Psychopharmacology (Berl)       Date:  2012-11-10       Impact factor: 4.530

6.  Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics.

Authors:  M Farré; R de la Torre; B O Mathúna; P N Roset; A M Peiró; M Torrens; J Ortuño; M Pujadas; J Camí
Journal:  Psychopharmacology (Berl)       Date:  2004-04-08       Impact factor: 4.530

7.  Hydrolysis of 3,4-methylenedioxymethamphetamine (MDMA) metabolite conjugates in human, squirrel monkey, and rat plasma.

Authors:  Melanie Mueller; Erin A Kolbrich-Spargo; Frank T Peters; Marilyn A Huestis; George A Ricaurte; Hans H Maurer
Journal:  Anal Bioanal Chem       Date:  2009-01-30       Impact factor: 4.142

8.  Human Pharmacology of Mephedrone in Comparison with MDMA.

Authors:  Esther Papaseit; Clara Pérez-Mañá; Julián-Andrés Mateus; Mitona Pujadas; Francina Fonseca; Marta Torrens; Eulàlia Olesti; Rafael de la Torre; Magí Farré
Journal:  Neuropsychopharmacology       Date:  2016-05-20       Impact factor: 7.853

9.  The relationship between core body temperature and 3,4-methylenedioxymethamphetamine metabolism in rats: implications for neurotoxicity.

Authors:  Beatriz Goni-Allo; Brian O Mathúna; Mireia Segura; Elena Puerta; Berta Lasheras; Rafael de la Torre; Norberto Aguirre
Journal:  Psychopharmacology (Berl)       Date:  2007-12-12       Impact factor: 4.530

10.  Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans.

Authors:  Tsadik T Abraham; Allan J Barnes; Ross H Lowe; Erin A Kolbrich Spargo; Garry Milman; Stephane O Pirnay; David A Gorelick; Robert S Goodwin; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2009-10       Impact factor: 3.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.